Skeletal formula
Space-filling model of zonampanel
Clinical data
ATC code
  • None
  • [7-(1H-Imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydro-1(2H)-quinoxalinyl]acetic acid
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass331.244 g·mol−1
3D model (JSmol)
  • c1cn(cn1)c2cc3c(cc2[N+](=O)[O-])[nH]c(=O)c(=O)n3CC(=O)O
  • InChI=1S/C13H9N5O6/c19-11(20)5-17-8-4-9(16-2-1-14-6-16)10(18(23)24)3-7(8)15-12(21)13(17)22/h1-4,6H,5H2,(H,15,21)(H,19,20)

Zonampanel (INN, code name YM872) is a quinoxalinedione derivative drug and competitive antagonist of the AMPA receptor which was being investigated by Yamanouchi/Astellas Pharma as a neuroprotective drug for the treatment of ischemic stroke but never completed clinical trials.[1][2][3][4] In clinical trials, zonampanel produced severe side effects including hallucinations, agitation, and catatonia in patients, resulting in early termination of the trials.[5]


  1. ^ Jain KK (14 February 2011). The Handbook of Neuroprotection. Springer Science & Business Media. pp. 154–. ISBN 978-1-61779-049-2.
  2. ^ Ray A, Gulati K (1 January 2007). Current Trends in Pharmacology. I. K. International Pvt Ltd. pp. 321–. ISBN 978-81-88237-77-7.
  3. ^ Waxman S (27 May 2005). Multiple Sclerosis As A Neuronal Disease. Academic Press. pp. 245–. ISBN 978-0-08-048941-4.
  4. ^ Gill S, Pulido O (31 January 2007). Glutamate Receptors in Peripheral Tissue: Excitatory Transmission Outside the CNS. Springer Science & Business Media. pp. 37–. ISBN 978-0-306-48644-9.
  5. ^ Farooqui AA (2 September 2010). Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases. Springer Science & Business Media. pp. 73–. ISBN 978-1-4419-6652-0.